ACR Meeting Abstracts

ACR Meeting Abstracts

  • Meetings
    • ACR Convergence 2024
    • ACR Convergence 2023
    • 2023 ACR/ARP PRSYM
    • ACR Convergence 2022
    • ACR Convergence 2021
    • ACR Convergence 2020
    • 2020 ACR/ARP PRSYM
    • 2019 ACR/ARP Annual Meeting
    • 2018-2009 Meetings
    • Download Abstracts
  • Keyword Index
  • Advanced Search
  • Your Favorites
    • Favorites
    • Login
    • View and print all favorites
    • Clear all your favorites
  • ACR Meetings

Abstract Number: 2408

A Prospective Analysis of Factors Impacting Medication Decision-Making in Patients with Rheumatoid Arthritis

Elizabeth Salt1, Amanda Wiggins 2, Kristine Lohr 2 and Mary Kay Rayens 2, 1University of Kentucky, Lexington, KY, 2University of Kentucky, Lexington

Meeting: 2019 ACR/ARP Annual Meeting

Keywords: Compliance and Disease Activity, Rheumatoid arthritis (RA)

  • Tweet
  • Click to email a link to a friend (Opens in new window) Email
  • Click to print (Opens in new window) Print
Session Information

Date: Tuesday, November 12, 2019

Title: RA – Treatments Poster III: Safety and Outcomes – ARP

Session Type: Poster Session (Tuesday)

Session Time: 9:00AM-11:00AM

Background/Purpose: Prior research suggests that medication decision-making in rheumatoid arthritis (RA) patients is affected by disease activity, satisfaction with care, trust in their health care provider, and quality of patient-provider communication.(1-3) Because few studies have used quantitative methodologies to do such, we will describe changes in these key decision-making factors over time.

Methods: We collected data over 6 months (baseline, 1 week, 8 weeks, 16 weeks and 24 weeks) in a sample of 143 RA patient at one University health system. We measured medication adherence with the Medication Adherence Report Scale-9RA, a 9-item scale using a 5-point Likert scale (5 = never and 1 = very often; score range: 9 – 45; Cronbach’s α =.77; test-retest reliability = .73).(4-6) Satisfaction with care was measured with the Client Satisfaction Questionnaire-8, an 8-item scale using a 4-point Likert-type scale where 4 indicates increased satisfaction (score range 8 – 32; Cronbach’s α = .93). A significant correlation with client-reported symptoms supports scale validity.(7) Trust in provider was measured with the Trust in Physician Scale (TPS), an 11-item scale using a 5-point Likert scale (1 = strongly disagree – 5 strongly agree; Cronbach’s α = .87).(8) The scale has significant negative correlations with measures of skepticism supporting scale validity.(8) Disease activity was measured with the Routine Assessment of Patient Index Data 3 (RAPID3) on three domains: physical function, pain, and patient global assessment on a scale of 0 to 10 (range 0 – 30).(9, 10) The RAPID3 has been significantly correlated with other measures of disease activity.(9, 10) We used repeated measure mixed modeling and Friedman’s test to describe the factors over time.

Results: We identified a significant decrease in the patient’s perceived quality of provider communication (p=.034), trust in the provider (p=.012) and satisfaction with care over time (p=.008). We did not identify changes over time in medication adherence, any of the four subscales measuring the patient’s perception of the quality of their communication with their health care provider, or disease activity overtime (Tables 1 and 2).

Conclusion: Despite stable medication adherence, disease activity did not change significantly over time. Although trust in the provider, satisfaction with care, and quality of provider communication scores were high, these values decreased over time suggesting that providers must make concerted efforts to maintain these key factors during the patient care experience.


Table 1.Prospective

Table 1. Repeated measures modeling of key factors over time.


Table 2.Prospectivedocx

Table 2. Disease activity over time.


citations

citations


Disclosure: E. Salt, Pfizer, 2, Pfizer and IHI, 2; A. Wiggins, Pfizer and IHI, 2; K. Lohr, Pfizer and IHI, 2; M. Rayens, Pfizer, 2, Pfizer and IHI, 2.

To cite this abstract in AMA style:

Salt E, Wiggins A, Lohr K, Rayens M. A Prospective Analysis of Factors Impacting Medication Decision-Making in Patients with Rheumatoid Arthritis [abstract]. Arthritis Rheumatol. 2019; 71 (suppl 10). https://acrabstracts.org/abstract/a-prospective-analysis-of-factors-impacting-medication-decision-making-in-patients-with-rheumatoid-arthritis/. Accessed .
  • Tweet
  • Click to email a link to a friend (Opens in new window) Email
  • Click to print (Opens in new window) Print

« Back to 2019 ACR/ARP Annual Meeting

ACR Meeting Abstracts - https://acrabstracts.org/abstract/a-prospective-analysis-of-factors-impacting-medication-decision-making-in-patients-with-rheumatoid-arthritis/

Advanced Search

Your Favorites

You can save and print a list of your favorite abstracts during your browser session by clicking the “Favorite” button at the bottom of any abstract. View your favorites »

All abstracts accepted to ACR Convergence are under media embargo once the ACR has notified presenters of their abstract’s acceptance. They may be presented at other meetings or published as manuscripts after this time but should not be discussed in non-scholarly venues or outlets. The following embargo policies are strictly enforced by the ACR.

Accepted abstracts are made available to the public online in advance of the meeting and are published in a special online supplement of our scientific journal, Arthritis & Rheumatology. Information contained in those abstracts may not be released until the abstracts appear online. In an exception to the media embargo, academic institutions, private organizations, and companies with products whose value may be influenced by information contained in an abstract may issue a press release to coincide with the availability of an ACR abstract on the ACR website. However, the ACR continues to require that information that goes beyond that contained in the abstract (e.g., discussion of the abstract done as part of editorial news coverage) is under media embargo until 10:00 AM ET on November 14, 2024. Journalists with access to embargoed information cannot release articles or editorial news coverage before this time. Editorial news coverage is considered original articles/videos developed by employed journalists to report facts, commentary, and subject matter expert quotes in a narrative form using a variety of sources (e.g., research, announcements, press releases, events, etc.).

Violation of this policy may result in the abstract being withdrawn from the meeting and other measures deemed appropriate. Authors are responsible for notifying colleagues, institutions, communications firms, and all other stakeholders related to the development or promotion of the abstract about this policy. If you have questions about the ACR abstract embargo policy, please contact ACR abstracts staff at [email protected].

Wiley

  • Online Journal
  • Privacy Policy
  • Permissions Policies
  • Cookie Preferences

© Copyright 2025 American College of Rheumatology